523 related articles for article (PubMed ID: 26093811)
1. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
2. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
3. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
4. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Lipton A; Fizazi K; Stopeck AT; Henry DH; Brown JE; Yardley DA; Richardson GE; Siena S; Maroto P; Clemens M; Bilynskyy B; Charu V; Beuzeboc P; Rader M; Viniegra M; Saad F; Ke C; Braun A; Jun S
Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
[TBL] [Abstract][Full Text] [Related]
5. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
[TBL] [Abstract][Full Text] [Related]
6. Denosumab and bone metastases. No better than a bisphosphonate.
Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
[TBL] [Abstract][Full Text] [Related]
7. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
8. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
[TBL] [Abstract][Full Text] [Related]
9. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
Imatoh T; Sai K; Takeyama M; Hori K; Karayama M; Furuhashi K; Segawa K; Kimura M; Kawakami J; Saito Y
J Clin Pharm Ther; 2019 Feb; 44(1):62-68. PubMed ID: 30144112
[TBL] [Abstract][Full Text] [Related]
10. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
11. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
12. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
13. Use and safety of denosumab in cancer patients.
Manzaneque A; Chaguaceda C; Mensa M; Bastida C; Creus-Baró N
Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
[TBL] [Abstract][Full Text] [Related]
14. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature.
Kreutle V; Blum C; Meier C; Past M; Müller B; Schütz P; Borm K
Swiss Med Wkly; 2014; 144():w13979. PubMed ID: 24964073
[TBL] [Abstract][Full Text] [Related]
16. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Lipton A; Smith MR; Fizazi K; Stopeck AT; Henry D; Brown JE; Shore ND; Saad F; Spencer A; Zhu L; Warner DJ
Clin Cancer Res; 2016 Dec; 22(23):5713-5721. PubMed ID: 27140926
[TBL] [Abstract][Full Text] [Related]
17. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
19. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan.
Imatoh T; Sai K; Takeyama M; Segawa K; Yamashita T; Nakashima N; Kataoka Y; Yokoi H; Hiramatsu T; Ohe K; Kimura M; Hori K; Kawakami J; Saito Y
J Clin Pharm Ther; 2019 Oct; 44(5):788-795. PubMed ID: 31282013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
